Skip to content

Evaluation of a Telephone Care Nurse in the Management of Patients With Cancer and Treated by Oral Chemotherapy

Evaluation of a Telephone Care Nurse in the Management of Patients With Cancer and Treated by Oral Chemotherapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02459483
Acronym
ETICCO
Enrollment
184
Registered
2015-06-02
Start date
2015-12-31
Completion date
2018-05-31
Last updated
2016-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

The purpose of this study is to assess the effectiveness of a nurse telephone interview in the management of cancer patients treated by oral chemotherapy. This is a multicenter prospective randomized controlled pragmatic interventional trial conducted in collaboration with two oncology care facilities. Eligible population consists of all patients suffering from advanced cancer and treated by oral chemotherapy except hormonotherapy. 184 patients will be enrolled in the study. The experimental group will receive a standard followed by a medical oncologist, hematologist or radiation therapist as part of routine care, and telephone interviews by a nurse every 14 +/- 2 days for 6 months. The control group will receive a standard followed by a medical oncologist, hematologist or radiation therapist as part of routine care. The effectiveness of the intervention will be evaluated by a toxicity score of the 9 most common side effects of oral cancer (oral mucositis, hand-foot syndrome, diarrhea, nausea, vomiting, pain, asthenia, rash and anorexia) officers from NCI CTCAE v4.0-(Common Toxicity Criteria for Adverse Events) and turned into a single composite criterion (sum of 9 Toxicity grades).

Interventions

Sponsors

Hôpital Privé de la Loire
CollaboratorUNKNOWN
Institut de Cancérologie de la Loire
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged over 18 years * treated in medical oncology, hematology or radiotherapy * to receive any oral chemotherapy for any cancer except hormone therapy according to decision of the Meeting of Consultation Multidisciplinary

Exclusion criteria

* Refusal of participation, protected adult patient under guardianship. * Patient currently treated with oral chemotherapy * Patient already included in another clinical research protocol including telephone follow-up * Patient followed by a Nurse navigators or participating in a therapeutic education program * Patient concomitantly treated with an injectable chemotherapy regimen or radiotherapy unless irradiation palliative analgesic. * Patient in inability to understand how the study or inability to follow a telephone conversation. * Patient with documented history of cognitive or psychiatric disorders. * Patient residing outside the Rhône Alpes area * Patient doesn't understand French * Patient with no phone means

Design outcomes

Primary

MeasureTime frameDescription
Toxicity score6 monthsToxicity Score 9 most common side effects of oral chemotherapy (oral mucositis, hand-foot syndrome, diarrhea, nausea, vomiting, pain, asthenia, rash and anorexia) officers from the NCI-CTCAE v4.0 (Common Toxicity Criteria for Adverse Events) and turned into a single composite criterion (sum of 9 toxicity grades)

Countries

France

Contacts

Primary ContactMathieu ORIOL, MD
mathieu.oriol@icloire.fr04 77 91 70 71

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026